Literature DB >> 20714746

Pigment epithelium-derived factor and vascular endothelial growth factor in branch retinal vein occlusion with macular edema.

Hidetaka Noma1, Hideharu Funatsu, Tatsuya Mimura, Seiyo Harino, Shuichiro Eguchi, Sadao Hori.   

Abstract

BACKGROUND: We investigated whether pigment epithelium-derived factor (PEDF) or vascular endothelial growth factor (VEGF) influence macular edema in patients with branch retinal vein occlusion (BRVO). This investigation aimed to clarify the influence of PEDF in the vitreous fluid on retinal vascular permeability in patients with macular edema secondary to BRVO. The findings were expected to be useful for the treatment of macular edema in BRVO patients.
METHODS: This was a retrospective cross-sectional comparative case series. Thirty-three BRVO patients with macular edema and 24 control patients with nonischemic ocular diseases were enrolled. Retinal ischemia was evaluated by measuring the area of capillary nonperfusion on fluorescein angiography with Scion Image software. Macular edema was examined by optical coherence tomography. Vitreous fluid samples were obtained via pars plana vitrectomy, and the VEGF and PEDF levels were determined by enzyme-linked immunosorbent assay.
RESULTS: The vitreous level of VEGF was significantly higher in BRVO patients than controls (P < 0.001). The vitreous PEDF level was significantly lower in BRVO patients than controls (P = 0.026). In BRVO patients, vitreous levels of PEDF and VEGF showed a significant negative correlation with each other (P < 0.001). Additionally, the vitreous VEGF level had a significant positive correlation (P < 0.001) and the vitreous PEDF level had a significant negative correlation (P < 0.001) with the nonperfused retinal area in BRVO patients. Furthermore, vitreous levels of VEGF and PEDF showed significant positive (P = 0.001) and negative (P = 0.014) correlations, respectively, with macular edema in BRVO patients.
CONCLUSIONS: VEGF and PEDF may inversely influence retinal vascular permeability in patients with ischemic BRVO and macular edema. However, prospective validation will be needed to confirm these observations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20714746     DOI: 10.1007/s00417-010-1486-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  33 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

Review 2.  The molecular structure and function of the inner blood-retinal barrier. Penn State Retina Research Group.

Authors:  T W Gardner; D A Antonetti; A J Barber; E Lieth; J A Tarbell
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

3.  Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.

Authors:  D W Dawson; O V Volpert; P Gillis; S E Crawford; H Xu; W Benedict; N P Bouck
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

4.  Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion.

Authors:  H Noma; H Funatsu; M Yamasaki; H Tsukamoto; T Mimura; T Sone; T Hirayama; H Tamura; H Yamashita; A Minamoto; H K Mishima
Journal:  Eye (Lond)       Date:  2006-07-07       Impact factor: 3.775

5.  Surgical posterior vitreous detachment combined with gas/air tamponade for treating macular edema associated with branch retinal vein occlusion: retinal tomography and visual outcome.

Authors:  S Saika; T Tanaka; T Miyamoto; Y Ohnishi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2001-10       Impact factor: 3.117

6.  Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family.

Authors:  F R Steele; G J Chader; L V Johnson; J Tombran-Tink
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

7.  Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator.

Authors:  Peter A Campochiaro; Gulnar Hafiz; Syed Mahmood Shah; Quan Dong Nguyen; Howard Ying; Diana V Do; Edward Quinlan; Ingrid Zimmer-Galler; Julia A Haller; Sharon D Solomon; Jennifer U Sung; Yasmin Hadi; Kashif A Janjua; Nida Jawed; David F Choy; Joseph R Arron
Journal:  Mol Ther       Date:  2008-02-05       Impact factor: 11.454

8.  PEDF derived from glial Müller cells: a possible regulator of retinal angiogenesis.

Authors:  Wolfram Eichler; Yousef Yafai; Thurid Keller; Peter Wiedemann; Andreas Reichenbach
Journal:  Exp Cell Res       Date:  2004-09-10       Impact factor: 3.905

9.  Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.

Authors:  Melvin D Rabena; Dante J Pieramici; Alessandro A Castellarin; Ma'an A Nasir; Robert L Avery
Journal:  Retina       Date:  2007 Apr-May       Impact factor: 4.256

10.  Hypoxic regulation of vascular endothelial growth factor in retinal cells.

Authors:  L P Aiello; J M Northrup; B A Keyt; H Takagi; M A Iwamoto
Journal:  Arch Ophthalmol       Date:  1995-12
View more
  9 in total

1.  Pigment epithelium-derived factor is related to macular microcirculation in patients with macular edema and branch retinal vein occlusion.

Authors:  Hidetaka Noma; Hideharu Funatsu; Tatsuya Mimura
Journal:  Int Ophthalmol       Date:  2012-05-19       Impact factor: 2.031

2.  Effects of arteriolar constriction on retinal gene expression and Müller cell responses in a rat model of branch retinal vein occlusion.

Authors:  Patricia Köferl; Margrit Hollborn; Jiri Rehak; Ianors Iandiev; Sladjana Dukic-Stefanovic; Peter Wiedemann; Leon Kohen; Andreas Bringmann; Matus Rehak
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-11-29       Impact factor: 3.117

3.  Estrogen-induced retinal endothelial cell proliferation: possible involvement of pigment epithelium-derived factor and phosphoinositide 3-kinase/mitogen-activated protein kinase pathways.

Authors:  Kalpana Parvathaneni; Jeffery G Grigsby; Brandi S Betts; Andrew T Tsin
Journal:  J Ocul Pharmacol Ther       Date:  2012-10-09       Impact factor: 2.671

4.  Inflammation in retinal vein occlusion.

Authors:  Avnish Deobhakta; Louis K Chang
Journal:  Int J Inflam       Date:  2013-04-03

5.  Visual prognosis and vitreous molecules after vitrectomy for macular edema with branch retinal vein occlusion.

Authors:  Hidetaka Noma; Hideharu Funatsu; Tatsuya Mimura; Shuichiro Eguchi; Katsunori Shimada
Journal:  Clin Ophthalmol       Date:  2011-02-15

6.  Influence of ischemia on visual function in patients with branch retinal vein occlusion and macular edema.

Authors:  Hidetaka Noma; Hideharu Funatsu; Tatsuya Mimura; Katsunori Shimada
Journal:  Clin Ophthalmol       Date:  2011-05-19

Review 7.  A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders.

Authors:  Lasse Jørgensen Cehofski; Bent Honoré; Henrik Vorum
Journal:  Int J Mol Sci       Date:  2017-04-28       Impact factor: 5.923

Review 8.  A Review of Intraocular Biomolecules in Retinal Vein Occlusion: Toward Potential Biomarkers for Companion Diagnostics.

Authors:  Bingjie Wang; Xiao Zhang; Huan Chen; Adrian Koh; Chan Zhao; Youxin Chen
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

9.  Role of inflammation in previously untreated macular edema with branch retinal vein occlusion.

Authors:  Hidetaka Noma; Tatsuya Mimura; Katsunori Shimada
Journal:  BMC Ophthalmol       Date:  2014-05-18       Impact factor: 2.209

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.